Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

NCT02433639 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: TH-302 monotherapy

Sponsor

Seoul National University Hospital

Collaborators

[object Object]